Judge blocks RFK Jr. vaccine policy overhaul

Good morning, healthcare professional.

Federal courts are intervening in vaccine policy, breakthrough obesity treatments are advancing through trials, and the pharmaceutical industry faces potential pricing upheaval. These developments signal a period of significant regulatory and clinical change across the healthcare landscape.

Today's digest examines how judicial action is shaping public health policy, why an oral GLP-1 formulation could transform obesity treatment, what a major RSV vaccine expansion means for prevention, and how most-favored nation pricing could reshape pharmaceutical economics. Each story carries implications that extend far beyond the headlines.

In today's healthcare digest:

• Federal judge halts HHS Secretary RFK Jr.'s vaccine policy changes
• Structure Therapeutics reports strong results for oral GLP-1 obesity pill
• GSK receives FDA approval to expand Arexvy RSV vaccine to younger adults
• White House advances most-favored nation drug pricing despite congressional resistance

Federal Judge Blocks RFK Jr.'s Vaccine Policy Overhaul

A federal judge has issued a temporary restraining order halting Health and Human Services Secretary Robert F. Kennedy Jr.'s planned overhaul of the nation's vaccine policy, including changes to the CDC's childhood immunization schedule and the Advisory Committee on Immunization Practices (ACIP). The ruling comes as multiple sources reported the judicial intervention that temporarily blocks the administration's vaccine policy changes.

Unpacked:

• The court order specifically targets proposed revisions to ACIP operations and the CDC immunization schedule that guides vaccination recommendations nationwide.
• Kennedy's planned changes had raised concerns among public health officials about potential disruption to established vaccination protocols affecting millions of children.
• The temporary restraining order provides time for full legal review while maintaining current vaccine policy frameworks during the challenge period.

Structure Therapeutics' Oral GLP-1 Pill Shows Best-in-Class Potential

Structure Therapeutics announced positive Phase 2 results for its oral GLP-1 drug aleniglipron in obesity treatment, with data suggesting best-in-class potential compared to current injectable options. The mid-stage trial demonstrated significant weight loss outcomes that could position the pill as a major competitor in the rapidly expanding obesity market.

Unpacked:

• The oral formulation addresses a key limitation of current GLP-1 therapies like Ozempic and Wegovy, which require regular injections.
• Trial participants achieved substantial weight reduction, with efficacy metrics approaching or matching injectable GLP-1 drugs currently dominating the market.
• Structure Therapeutics now faces competition from multiple companies developing oral GLP-1 candidates, including Pfizer, Lilly, and Novo Nordisk.

GSK's Arexvy RSV Vaccine Gains FDA Approval for Younger Adults

The FDA has expanded approval for GSK's Arexvy RSV vaccine to include younger adults, bringing the company into competitive parity with Pfizer and Moderna in this age demographic. The approval broadens the eligible population for RSV vaccination beyond the initial older adult indication.

Unpacked:

• GSK now matches the age range approvals held by competitors Pfizer's Abrysvo and Moderna's mRESVIA for RSV prevention.
• The expanded indication opens a larger market opportunity as RSV vaccines compete for share across multiple adult age groups.
• This approval comes as the RSV vaccine market continues to develop following the 2023 introduction of the first vaccines for this respiratory virus.

White House Pushes Most-Favored Nation Drug Pricing Despite Congressional Pushback

The White House is maintaining its push for most-favored nation drug pricing despite a cool reception from Congress, setting up a potential clash over pharmaceutical pricing policy. The proposal would tie U.S. drug prices to lower rates paid in other developed countries.

Unpacked:

• Most-favored nation pricing has been debated for years as a mechanism to reduce U.S. drug costs by referencing international prices.
• Congressional resistance reflects concerns about implementation challenges, potential supply disruptions, and pharmaceutical industry opposition to mandatory price controls.
• The policy divide highlights ongoing tension between executive action on drug pricing and legislative authority over healthcare economics.

The Shortlist

• Bayer heads to regulators with positive trial data for Kerendia in nondiabetic chronic kidney disease, potentially doubling the eligible patient population.

• Eli Lilly reported positive results for Ebglyss in younger children with eczema, setting up a potential label expansion into pediatric populations.

• CytomX Therapeutics saw shares surge after positive data for its masked antibody-drug conjugate in colorectal cancer treatment.

• Johnson & Johnson filed a trade secret lawsuit against a former oncology employee linked to Summit Therapeutics over alleged proprietary information misuse.

• Amgen and GSK joined TrumpRx, the government's direct-to-consumer prescription drug platform, expanding the program's formulary.